Renzapride

DB04917

small molecule investigational

Deskripsi

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.

Struktur Molekul 2D

Berat 323.818
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

677 Data
Buprenorphine Renzapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Hydrocodone Renzapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Magnesium sulfate The therapeutic efficacy of Renzapride can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Renzapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Renzapride may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Mirtazapine Renzapride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Orphenadrine Renzapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Renzapride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Pramipexole Renzapride may increase the sedative activities of Pramipexole.
Ropinirole Renzapride may increase the sedative activities of Ropinirole.
Rotigotine Renzapride may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Renzapride.
Sodium oxybate Renzapride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Renzapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Thalidomide Renzapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Renzapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Renzapride.
Dicoumarol The risk or severity of adverse effects can be increased when Renzapride is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Renzapride is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Renzapride is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Renzapride is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Renzapride is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Renzapride is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Renzapride is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Renzapride is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Renzapride is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Renzapride is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Renzapride is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Renzapride is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Renzapride is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Renzapride is combined with (S)-Warfarin.
Ethanol Renzapride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Renzapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Fluvoxamine The risk or severity of adverse effects can be increased when Renzapride is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Renzapride is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Renzapride is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Renzapride is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Renzapride is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Renzapride is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Renzapride is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Renzapride is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Renzapride is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Renzapride is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Renzapride is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Renzapride is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Renzapride is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Renzapride is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Renzapride is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Renzapride is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Renzapride is combined with Alaproclate.
Zopiclone The risk or severity of adverse effects can be increased when Renzapride is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Renzapride.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Renzapride.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Renzapride.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Renzapride.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Renzapride.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Renzapride.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Renzapride.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Renzapride.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Renzapride.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Renzapride.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Renzapride.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Renzapride.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Renzapride.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Renzapride.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Renzapride.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Renzapride.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Renzapride.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Renzapride.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Renzapride.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Renzapride.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Renzapride.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Renzapride.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Renzapride.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Renzapride.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Renzapride.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Renzapride.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Renzapride.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Renzapride.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Renzapride.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Renzapride.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Renzapride.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Renzapride.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Renzapride.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Renzapride.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Renzapride.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Renzapride.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Renzapride.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Renzapride.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Renzapride.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Renzapride.

Target Protein

5-hydroxytryptamine receptor 4 HTR4
5-hydroxytryptamine receptor 3A HTR3A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2338113
    Staniforth DH, Pennick M: Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties. Eur J Clin Pharmacol. 1990;38(2):161-4.
  • PMID: 1888816
    Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR: The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther. 1991 Apr;5(2):135-42.
  • PMID: 1364818
    Craig DA, Clarke DE: Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4 receptor activation. Br J Pharmacol. 1991 Mar;102(3):563-4.
  • PMID: 16696817
    Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RM: Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1655-65.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul